Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | TP53 | P04637 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.79 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.79 |
| ▸ | RELA | Q04206 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | THRB | P10828 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983269 | 0.92 | MAPT (0.84) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL31364277 | 0.89 | MAOB (0.81) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL17786334 | 0.89 | EGFR (0.67) | MAPTTP53CYP3A4NPC1RAB9A | |
| 6,4'-Dimethoxyflavone SCHEMBL4281291 | 0.88 | MAPT (1.00) | MAPTTP53CYP3A4NPC1RAB9A | |
| 6,4'-Dimethoxyflavone SCHEMBL29478471 | 0.88 | MAPT (1.00) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL17786503 | 0.85 | EGFR (0.70) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL7079959 | 0.85 | KDM4E (0.73) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL535143 | 0.84 | KCNA5 (1.00) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL31238310 | 0.84 | MAPT (0.91) | MAPTTP53CYP3A4NPC1RAB9A | |
| SCHEMBL17786381 | 0.84 | FYN (0.73) | MAPTTP53CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016083490-A1 | COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES | REMYND NV (BE) | 2016-06-02 | — | — | WO | disclosed |
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| EP-2268628-B1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| EP-2268628-B1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| EP-2268628-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | Rottapharm S.p.A. (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009109230-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109230-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | NAT1, AADAC, OPRL1 | MAPT 4791/4885TP53 1809/4885CYP3A4 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.